StockGuide AI - assistant for market research

Analysts expect Danaher (DHR) to accelerate earnings growth following Masimo acquisition and recovery in bioprocessing demand

07/16/2026, 11:35 AM investing forecast Analysts: analysts healthcare

Danaher is positioned for a significant earnings recovery as it emerges from a pandemic-induced destocking cycle, bolstered by its recent acquisition of Masimo and a rebound in bioprocessing demand. Investors may find the stock undervalued given its improving fundamentals and growth catalysts.

United Airlines Reports Mixed Earnings Amid Rising Fuel Costs, While UnitedHealth Exceeds Expectations and Raises Profit Outlook

07/16/2026, 05:36 AM economy review finance healthcare

Recent economic indicators suggest a potential easing of inflation, which could influence Federal Reserve interest rate decisions. Additionally, United Airlines faces rising fuel costs despite beating earnings expectations, while UnitedHealth's strong performance and Anthropic's IPO preparations highlight significant movements in the healthcare and tech sectors.

UnitedHealth Group Reports Strong Q2 Earnings, Raises Full-Year Profit Outlook Amid Cost Management Efforts

07/16/2026, 03:35 AM business forecast healthcare

UnitedHealth Group's strong second-quarter earnings and raised profit outlook highlight its effective cost management and AI integration, signaling potential growth despite ongoing challenges in the healthcare sector.

Analysts raise Johnson & Johnson (JNJ) target price despite stock decline following strong earnings report

07/15/2026, 01:36 PM business rating_growth Analysts: analysts healthcare

Johnson & Johnson's shares declined despite a strong second-quarter earnings report and an upward revision of its full-year guidance, indicating that the market may not fully appreciate the company's long-term growth potential.

Johnson & Johnson Reports Strong Q2 Earnings, Boosts Full-Year Forecast Amid Growth in Pharmaceuticals

07/15/2026, 05:36 AM forecast healthcare

Johnson & Johnson's second-quarter results exceeded Wall Street expectations, driven by strong sales from its immunology and cancer drugs, prompting the company to raise its full-year sales and profit forecasts.

Analysts highlight IQVIA (IQV) and Danaher (DHR) as leading biotech stocks poised for recovery

07/14/2026, 09:38 AM investing review Analysts: analysts biotech healthcare

The biotechnology sector, which has faced significant challenges in recent years, is showing signs of recovery, presenting potential investment opportunities in companies like IQVIA, Danaher, and Vertex Pharmaceuticals. This shift is driven by stabilizing funding conditions, increased clinical trial activity, and the need for pharmaceutical companies to innovate as patent expirations loom.

Novo Nordisk Partners with Vivani Medical to Develop GLP-1 Implant for Long-Term Weight Loss Maintenance

07/11/2026, 05:31 AM business announcement healthcare

Vivani Medical is developing a GLP-1 implant aimed at helping patients maintain weight loss long-term, addressing challenges associated with current treatments. This innovation could significantly impact the obesity treatment market, which is projected to exceed $100 billion by the early 2030s.

Analysts BMO Capital Markets initiated coverage of Intuitive Surgical (ISRG) with outperform rating, citing strong growth prospects

07/10/2026, 10:36 AM investing rating_growth Analysts: analysts, BMO healthcare

As earnings season approaches, several companies known for consistently exceeding Wall Street expectations are set to report next week, which could influence market sentiment and stock performance.

AstraZeneca (AZN) Shares Drop 9% Following Heart Drug Trial Failure

07/09/2026, 01:35 AM business stock_drop healthcare

AstraZeneca's shares dropped nearly 9% following the failure of its late-stage clinical trial for the heart drug Wainua, which did not achieve its primary goal of reducing deaths and heart-related emergencies.

Employers Remain Reluctant to Expand Coverage for GLP-1 Obesity Drugs Despite Rising Demand

07/08/2026, 06:36 AM business review healthcare

Despite the introduction of new GLP-1 drugs and Medicare coverage for obesity, employer coverage for these medications remains stagnant, primarily due to high costs. This trend could impact the market for GLP-1 drugs and the overall healthcare landscape as employers seek alternative ways to support employee health.

Topic: healthcare